Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
April 20, 2010
Separation and detection of all phosphoinositide isomers by ESI-MS
Sabine Kiefer, Johannes Rogger, Anna Melone, et al.
Aging Clinical and Experimental Research
|
June 1, 2019
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial
Emilia Salvadori, Anna Poggesi, Ida Donnini, et al.
Drugs & Aging
|
April 15, 2021
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial
Emilia Salvadori, Anna Poggesi, Ida Donnini, et al.
Allergy
|
November 6, 2024
Basophil activation test: How many basophils are enough?
Léonard Bezinge, Dominik Vogt, Anna Melone, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety
Chiara Borsari, Denise Rageot, Florent Beaufils, et al.
Neuropharmacology
|
August 7, 2018
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Claudia Brandt, Petra Hillmann, Andreas Noack, et al.
Journal of Medicinal Chemistry
|
August 30, 2019
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
Chiara Borsari, Denise Rageot, Alix Dall'Asen, et al.
Journal of Medicinal Chemistry
|
October 26, 2018
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
Denise Rageot, Thomas Bohnacker, Anna Melone, et al.
Chimia
|
May 21, 2021
Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein
Larissa Brosi, Eric Kübler, Anna Weston, et al.
Journal of Medicinal Chemistry
|
November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders
Chiara Borsari, Erhan Keles, Denise Rageot, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Journal of Pharmaceutical and Biomedical Analysis
|
April 20, 2010
Separation and detection of all phosphoinositide isomers by ESI-MS
Sabine Kiefer, Johannes Rogger, Anna Melone, et al.
Aging Clinical and Experimental Research
|
June 1, 2019
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial
Emilia Salvadori, Anna Poggesi, Ida Donnini, et al.
Drugs & Aging
|
April 15, 2021
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial
Emilia Salvadori, Anna Poggesi, Ida Donnini, et al.
Allergy
|
November 6, 2024
Basophil activation test: How many basophils are enough?
Léonard Bezinge, Dominik Vogt, Anna Melone, et al.
ACS Medicinal Chemistry Letters
|
October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety
Chiara Borsari, Denise Rageot, Florent Beaufils, et al.
Neuropharmacology
|
August 7, 2018
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Claudia Brandt, Petra Hillmann, Andreas Noack, et al.
Journal of Medicinal Chemistry
|
August 30, 2019
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
Chiara Borsari, Denise Rageot, Alix Dall'Asen, et al.
Journal of Medicinal Chemistry
|
October 26, 2018
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
Denise Rageot, Thomas Bohnacker, Anna Melone, et al.
Chimia
|
May 21, 2021
Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein
Larissa Brosi, Eric Kübler, Anna Weston, et al.
Journal of Medicinal Chemistry
|
November 9, 2020
4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders
Chiara Borsari, Erhan Keles, Denise Rageot, et al.
Page
of 2